TACSTD2 and colorectal carcinoma: A higher prevalence of PD-L1+ tumors was observed in CRC TACSTD2-high versus TACSTD2-low tumors (6.4% vs 3.9%), with the opposite pattern observed in urothelial cancer (16% vs 37%; Figure 3A).